Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.65 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.65 |
| ▸ | KRAS | P01116 | 4/20 | 0.64 |
| ▸ | HINT1 | P49773 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.59 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.59 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.59 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.59 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.59 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20850061 | 1.00 | NT5E (0.71) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL28165608 | 1.00 | NT5E (0.71) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL18648315 | 1.00 | NT5E (0.71) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL28275952 | 0.95 | NT5E (0.75) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL21413213 | 0.94 | NT5E (0.70) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL27819299 | 0.94 | NT5E (0.74) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL28222628 | 0.94 | NT5E (0.74) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL8501729 | 0.94 | NT5E (0.74) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL574773 | 0.94 | NT5E (0.74) | NT5ETGM2FUT5IMPDH2IMPDH1 | |
| SCHEMBL4366555 | 0.93 | NT5E (0.73) | NT5ETGM2FUT5IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751925-B2 | Alternative nucleic acid molecules containing reduced uracil content and uses thereof | MODERNATX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9597380-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-18 | — | — | US | disclosed |
| US-20160237134-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-18 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20140147454-A1 | TERMINALLY MODIFIED RNA | MODERNA THERAPEUTICS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885TGM2 1916/4885FUT5 1042/4885 |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | NT5E 35/4885TGM2 2867/4885FUT5 1345/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885TGM2 1916/4885FUT5 1042/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885TGM2 1916/4885FUT5 1042/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885TGM2 2234/4885FUT5 2056/4885 |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885TGM2 1916/4885FUT5 1042/4885 |
| US-20160237134-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | RNMT, NSUN2, ADAR | NT5E 152/4885TGM2 1926/4885FUT5 1862/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885TGM2 1916/4885FUT5 1042/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885TGM2 2234/4885FUT5 2056/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | NT5E 67/4885TGM2 2234/4885FUT5 2056/4885 |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885TGM2 1916/4885FUT5 1042/4885 |
| US-20140147454-A1 | TERMINALLY MODIFIED RNA | RNGTT, NSUN3, RNMT | NT5E 234/4885TGM2 3781/4885FUT5 641/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | NT5E 32/4885TGM2 1916/4885FUT5 1042/4885 |
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | NSUN3, POLRMT, TRDMT1 | NT5E 97/4885TGM2 2945/4885FUT5 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.